• Head trauma induces calpain hyperactivation in neurons and glial cells.
a b s t r a c t
The normal cellular prion protein (PrP C ) is a sialoglycoprotein with a glycophosphatidylinositol anchor and expressed in highest levels within the CNS particularly at neuronal synapses. This membrane-bound protein is involved with many cell functions including cell signaling and neuroprotection.
Calpains are calcium-activated cysteine proteases that typically undergo controlled activation. PrP C is a calpain substrate and is neurotoxic if it undergoes aberrant processing with cytosol accumulation. Following traumatic brain injury (TBI), there is an abnormal influx of Ca +2 and overactivation of calpains resulting in neuronal dysfunction and cell death. We investigated whether PrP C expression and calpain activity have an effect on, or are affected by, TBI. PrP C expression in the hippocampus, cortex and cerebellum of WT and Tga20 (PrP C overexpression) mice were unchanged after closed head injury (CHI). Further, PrP C in WT and Tga20 mice was resistant to TBI-induced calpain proteolysis.
CHI-induced calpain activation resulted in breakdown products (BDPs) of ␣II-spectrin (SBDPs) and GFAP (GBDP-44 K) in all brain regions and mouse lines. CHI caused significant increases in SBDP145, GFAP and GBDP-44 K when compared to sham. With few exceptions, the calpain inhibitor, SNJ-1945, reduced SBDP145 and GBDP-44 K levels. Behavioral studies suggested that PrP C and calpain independently affect learning and memory. Overall, we conclude that: (i) there is SNJ-1945-sensitive calpain activation in both neuron and glial cells following CHI, (ii) closed head trauma is not affected by, nor does it have an influence on, PrP C expression, and (iii) PrP C expression plays a minor role, if any, in CHI-induced calpain activation in vivo.
© 2016 Elsevier B.V. All rights reserved.
Introduction
The cellular prion protein (PrP C ) is involved in a number of cellassociated processes, such as the regulation of cell death [1] [2] [3] , protection against oxidative stress [4, 5] , copper binding [6, 7] the modulation of several signal transduction pathways known to promote cellular survival [8] [9] [10] , however, the actual physiological function of the prion protein remains ambiguous. The role of PrP C in the regulation of cell death is undisputed. Introducing PrP C into PrP C -deficient hippocampal neurons undergoing apoptosis rescued the apoptotic phenotype [1] . Moreover, studies in vivo demonstrated that physiological levels of PrP C exert a neuroprotective effect following acute seizures or an ischemic injury [11] [12] [13] . Conversely, overproducing PrP C in different cell lines appears to sensitize cells to apoptosis through the control of p53 activity [3] and to have a detrimental effect in vivo [14, 15] . Therefore, the level of PrP C expression seems to be critical for the decision between pro-and anti-apoptotic phenotypes. PrP C has also been found to mediate amyloid-␤-oligomer-induced synaptic dysfunction [16] .
PrP C is extracellular with a glycosyl-phosphatidylinositol anchor that interdigitates only the outer leaflet of the cell membrane, raising the possibility that shear forces can release membrane associated PrP C into the systemic circulation. Thus, PrP C may serve as a potential biomarker for traumatic brain injury (TBI) following a blast [17] .
TBI is a major global problem affecting approximately 10 million people every year. Clinical assessment and neuroimaging continue to be used in the diagnosis of, and prognosis for, TBI. However, the level of subjectivity in these clinical assessments has resulted in interest in the identification of protein biomarkers to aid in the assessment for TBI. This is especially applicable for blast and mild TBI cases given the potential absence of physical symptoms or the presence of nonspecific ones that confound the recognition of mild indications such as sleep disturbance, fatigue, headaches, and loss of concentration that are often overlooked and underreported. Typical markers for brain injury that may be useful for diagnosis of TBI include proteins such as S100B, glial fibrillary acidic protein (GFAP) and its breakdown products (GBDP), Ubiquitin C-terminal hydrolase L1 (UCH-L1), neuron specific enolase (NSE), cleaved tau (C-tau), and variety of others [18] [19] [20] [21] [22] [23] .
TBI disrupts calcium homeostasis, which activates the neutral cysteine protease, calpain. Calpain promotes neuronal damage and proteolysis of neuronal-cytoskeletal elements. Calpain activation results in the cleavage of the cytoskeleton protein ␣II-spectrin to generate the spectrin breakdown products (SBDPs) SBDP150 and SBDP145 [24, 25] . On the other hand, SBDP120 also increases after TBI but is produced by caspase-3 and has a later appearance and longer time course of accumulation compared to SBDP150 and SBDP145. From these studies it has been suggested that ␣II-spectrin breakdown to a 150 kDa and 145 kDa doublet is present in necrotic neuronal death and neuronal apoptosis while SBDP120 is present only in apoptotic neurons. Since the level of SBDP150 and SBDP145 are proportional to the severity of the brain injury, they may serve as biomarkers for TBI severity and clinical course.
GFAP is a relatively brain-specific protein that resides in the astroglial cells [53] and the formation of GBDPs by calpain has been found after brain injury [33, 34, 53] . The release of GFAP and/or GFAP BDPs into serum after TBI [26, 54] has been described previously by us and others [26, 53] .
Since there is a direct correlation between calpain activation and neurodegeneration caused by trauma, inhibiting calpain is a potential therapeutic approach to TBI. SNJ-1945 is a water soluble calpain inhibitor (Senju Pharmaceutical Co., Ltd, Osaka and Kobe, Japan). SNJ-1945 inhibits both calpain 1 and calpain 2, the two major calpain isoforms, about equally at 170 nM and 99 nM, respectively [55] . This experimental drug has been used to treat diseases associated with calpain activation such as retinal degeneration [27, 28] , prevention of retinal ganglionic cell death [29] , and as a neuroprotective agent in animal models of stroke [30] and TBI [31] .
In this report we used three different strains of mice expressing different levels of PrP C to examine: 1) the influence of endogenous PrP C levels on an animal's response to severe TBI (sTBI) as monitored by changes in central nervous system (CNS) biomarkers, and 2) the effect of sTBI on PrP C -linked neuroprotection and neurodegeneration.
Materials and methods

Mice
All animal studies were carried out in accordance with the National Institutes of Health guide for the care and use of laboratory animals and under the supervision and approval of the Institution Animal Care and Use Committee. Breeding pairs of PrP knockout (PrPKO) mice and PrP overexpressing (Tga20) mice were originally supplied by Dr. Charles Weissman (Scripps Research Institute, FL) and have been continually bred and maintained at SUNY Downstate Medical Center. The wild-type (WT) mice were generated in-house. The background genotype of all mice used in this study was C57BL/6J x 129/SV.
Animal model of TBI (mouse closed head injury)
A baseline weight was obtained for WT, PrPKO and Tga20 mice prior to severe closed head injury (CHI) or sham-CHI. Deep anesthesia was induced with isoflurane [3% in oxygen (1.0 l/min)] and maintained via a nose cone and isoflurane [2% in oxygen (1.0 l/min)]. The head of the mouse was fixed in a stereotaxic frame. Temperature was maintained at 36.5-37.5 • C using a circulating warm water heating pad. Isoflurane anesthesia was maintained throughout the procedure. A cortical contusion was produced using an electromagnetic contusion device (Myneurolab, St. Louis, MO). A 5.0 mm diameter impactor tip was placed at a 10 • angle 5.0 mm off the midline and 5.0 mm from the eyes of the mouse. CHI was produced by a single impact to the skull at 6.3 m/s. velocity and 3 mm depth and a dwell of 0.2 msec. After the impact the mouse was removed from the device and allowed to recover on the heating pad and then placed in its home cage. A mouse was determined to have recovered from anesthesia if it regained its ability to right itself and ambulate. Control (sham) mice received the same procedure without the impact. Mice were weighed every day after CHI or sham-CHI.
Calpain inhibitor SNJ-1945 formulation and administration in vivo
Calpain was inhibited by intraperitoneal (i.p.) administration of SNJ-1945 (100 mg/kg) at 3 and 24 h post CHI or sham. SNJ-1945 was prepared as a stock concentration of 3 mg/ml in 0.5% carboxymethyl cellulose (CMC) in sterile distilled water. To prepare the SNJ-1945 stock suspension, the weighed amount of SNJ-1945 is ground up with a mortar and pestle in the presence of 200 l 0.5% CMC. When the prepared SNJ can pass through a 22 g needle, add 0.5% CMC to the desired final volume. SNJ-1945 was prepared fresh as needed.
Western blots and quantification
At 1, 3 and 7 days post-CHI blood was collected into heparinized capillary tubes from mice while under isoflurane anesthesia. The tubes were centrifuged at 10,000g for 2-3 min and the plasma fraction was collected. Mice were euthanized and their brains dissected into ipsilateral (relative to the injury) and contralateral cortex, hippocampus, and cerebellum regions. The brain tissues were quick-frozen at −80 • C. The soluble fractions were generated by first preparing 10% brain homogenates in a Triton X-100 lysis Brain tissue was processed and insoluble fractions were western blotted and immunostained for PrP C using the PrP-specific Mab 11F12. Protein bands were quantitated using densitometric analysis (Image J). Naive mice received no treatment whereas sham mice were treated the same as CHI mice but without head injury. For each of the 10 individual groups, and at each of the 3 time points, 3-5 mice were used. Western blotting was performed a minimum of 2 times for each sample with repeat Western blotting performed on separate days. The mean ± SEM of the densitometry data was calculated and plotted. (B) Quantitation of PrP C in the ipsilateral hippocampus of Tga20 mice. Male and female mice were either grouped as naive, severe CHI or sham treated. Following CHI (or sham), mice were administered SNJ-1945 at 3 and 24 h after CHI (or sham) and at days 1, 3 and 7 post injury, mice were bled, euthanized and their brains removed. Brain tissue was processed and insoluble fractions were western blotted and immunostained for PrP C using the PrP-specific monoclonal antibody 11F12. Protein bands were quantitated using densitometric analysis (Image J). For each of the 10 individual groups, and at each of the 3 time points, 3-5 mice were used. Western blotting was performed a minimum of 2 times for each sample with repeat Western blotting performed on separate days. The mean ± SEM of the densitometry data was calculated and plotted.
buffer (20 mM Tris-HCl, pH 7.4, 150 mM NaCl, 5 mM EDTA, 5 mM EGTA, 1% Triton X-100, 1 mM DTT, 100x protease inhibitor cocktail, 1 mM Na-vanadate). Homogenates were incubated on ice for 30 min. They were then centrifuged at 4 • C for 15 min and the supernatants were harvested as "soluble fractions". The pellets were resuspended in RIPA buffer (50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 5 mM EDTA, 0.5% NP40, 0.5% Na-deoxycholate, 0.2% SDS, 100× protease inhibitor) at one-third the volume of Triton X-100 lysis buffer used for preparing soluble fractions, heated at 100 • C for 10 min Supernatants from the dissolved pellets were collected after centrifugation at room temp for 15 min and termed "insoluble fractions".
Soluble fractions were subjected to western blotting to independently assess neuronal injury [␣II-spectrin (fodrin) and spectrin breakdown products (SBDPs)], gliosis (GFAP) and glial cell injury (GFAP and GBDPs) [32] [33] [34] . Insoluble fractions were used to analyze PrP C . Briefly, for SDS-polyacrylamide gel electrophoresis (SDS-PAGE), the fractions were loaded onto 12% mini-gels (PrP C ) or Tris-Glycine 4-20% gradient mini-gels (spectrin, SBDPs, GFAP, GBDPs) (Life Technologies/Invitrogen) [35] . Because of the high levels of PrP C expression in Tga20 mice, we loaded 5 g protein per lane for PrP C analysis of Tga20 samples. For all other samples and analysis, we loaded 20 g protein per lane.
Following electrophoresis, separated proteins were laterally transferred to polyvinylidene fluoride (PVDF) membranes (iBlot semi-dry transfer system). After electrotransfer, the membranes were blocked for 1 h at ambient temperature in 5% non-fat milk prepared in Tris-buffered saline containing 0.05% Tween-20 (TBST) followed by incubation at 4 • C for 3 h or overnight with primary antibodies [mouse anti-PrP monoclonal antibody (Mab) 11F12 (1:10,000), anti-␣II-spectrin Mab (1:2000) (Biomol) or rabbit anti-GFAP (1:2000) (Abcam) in TBST-5% non-fat milk. After washing with TBST, blots were incubated with alkaline phosphataseconjugated secondary antibody (goat anti-rabbit or anti-mouse IgG) (Novagen) for 1-2 h and following further washing, blots were developed with substrate BCIP-NBT reagent (KPL). A housekeeping protein, carbonic anhydrase-II (CA-II) was included as an internal sample loading control. Quantitative evaluation of target protein levels was performed via computer-assisted densitometric scanning (Epson XL3500 scanner, Long Beach, CA, USA) and image analysis with Image J software (version 1.6) (NIH). Protein quantitative data presented are averages of band density of brain lysate samples from individual mice using 3-5 mice/group. Data is calculated as mean ± SEM.
Post-CHI behavior assessment
Behavioral assessment utilized an active place avoidance apparatus (BioSignal Group Corp., Brooklyn, NY) [35] with a 40 cm diameter metal disc and prominent visual landmarks on the walls. Computer tracking of the position of a mouse was accomplished using a computer controlled Firewire camera mounted above the arena. The outer part of the arena was marked with a light emitting diode (LED). The positions of the mouse and the arena LED were used to calculate the movement of the animal relative to the arena. The computer defined a 60 • segment of the arena as a donot-enter shock zone. A 0.2 mA shock (60 Hz) was applied at 500 ms through the grid floor after entry into the shock zone. Additional shocks were administered every 1.5 s until the mouse vacated the shock zone. The number of times a mouse entered the shock zone was computed by Track Analysis software (BioSignal Group Corp., Brooklyn, NY).
Beginning 7 days after CHI or sham-CHI, mice had a 10 min pretraining (open field) session in which they were placed into the arena with the shock zone turned off and the platform moving at 1 rotation per min (rpm). The mice were then tested in 4 sessions, 10 min each with a 50 min inter-trial interval with the shock zone turned on. The number of shock zone entrances and the distance traveled were assessed. Compared to sham mice, the sum of shock zone entrances of CHI mice after 4 trials was inversely correlated to cognitive function.
Results
Effects of PrP c expression and SNJ-1945 on brain ˛II-spectrin
and GFAP biomarker levels post-CHI PrP C levels in the brains of the three mouse lines were previously compared [36, 37] and repeated here (data not shown). The PrPKO mice had no detectable PrP C in 10% brain homogenates as expected. In contrast, when compared by end-point dilution, the level of PrP C in Tga20 mouse brain was approximately 8 times greater than WT and showed the typical three banding pattern: diglycosylated, monoglycosylated and unglycosylated forms of the protein [38] .
We used mouse lines with varying levels of PrP C expression (WT, PrPKO, Tga20) to evaluate the neuro-and glia-protective properties of both PrP C and calpain inhibition, as well as their potential inter-play, following CHI. Calpain was inhibited by i.p. administration of SNJ-1945 (100 mg/kg) at 3 and 24 h post CHI or sham. We analyzed brain extracts from the ipsilateral hippocampus, cortex and cerebellum at 1, 3 and 7 days post CHI for PrP C expression and three classes of TBI biomarkers: (i) neuronal injury [␣II-spectrin and ␣II-spectrin breakdown products (SBDPs)], (ii) gliosis (GFAP) and (iii) glial cell injury (GFAP and its BDPs) [31] [32] [33] .
Unexpectedly, throughout the 7 day study period PrP C expression levels were not significantly altered following CHI in the ipsilateral hippocampus of male and female WT (Fig. 1A) and Tga20 (Fig. 1B) mice compared to the sham-treated animals. Similarly, following CHI the PrP C levels in the cortex and cerebellum of WT and Tga20 mice remained relatively unchanged compared to sham controls (data not shown). Further, calpain inhibition with SNJ-1945 did not alter the PrP C profiles or the level of endogenous PrP C in WT and Tga20 brain in the hippocampus (Fig. 1A, B) or in the cortex and cerebellum (data not shown).
In the ipsilateral hippocampus of all three mouse lines (WT, PrPKO, Tga20), in contrast to sham controls, CHI activated calpain as demonstrated by a significant increase in the neural injury-linked, calpain-generated ␣II-spectrin breakdown products, SBDP150/SBDP145 at days 1, 3 and 7 (Suppl. Fig. S1 , Table 1 ). At all time points the CHI-induced increase in SBDP145 was significantly different than the sham controls in all three mouse lines while only Tga20 consistently differed from the WT and PrPKO at all times when the three mouse lines were compared to each other. SBDP145 levels were highest on day 1 and/or day 3. We also observed more varied and low levels of caspase-mediated SBDP120 at days 1, 3 and 7 post-CHI in all three mouse lines (arrowheads in Suppl. Fig.  S1 ). Since SBDP120 levels were much lower and more variable than those of SBDP145, they were not quantified.
We also observed significant increases in the level of gliosisassociated intact GFAP (50 kDa) in the hippocampus on day 3 post CHI in all three mouse lines, as well as on day 7 in WT and Tga20 mice (Suppl. Fig. S1, Fig. 2, Table 1 ). Furthermore, the glial cell injury marker, GBDP-44K (the 44 kDa GFAP breakdown product), progressively increased throughout the 7 day period post CHI in the three mouse lines (Suppl. Fig. S1, Fig. 2) .
We observed the highest levels of SBDP145 in the hippocampus of WT mice on day 1 post CHI with less in PrPKO and the lowest amount in Tga20. The levels continued to decrease proportionately in the mouse lines until day 7 (Suppl. Fig. S1, Fig. 2, Table 1 ).
In the ipsilateral cortex, we again observed that, compared to sham controls, CHI activated calpain as detected by significant increases of SBDP150 and SBDP145 in all three mouse lines (WT, PrPKO, Tga20) at all three time points for WT and PrPKO and at days 1 and 3 for Tga20 (Suppl. Fig. S2, Fig. 3 , Table 2 ). Similar results, albeit with lower absolute values, were found in the ipsilateral cerebellum where the levels of SBDP145 in the three mouse lines post CHI were significantly different than their corresponding sham controls at all time points (Suppl. Fig. S3, Fig. 4, Table 3 ). These lower levels are consistent with the fact that the impact focal point was targeted over the forebrain cortical region, rather than the hindbrain region where the cerebellum is located. For both the cortex (Suppl. Fig. S2, Fig. 3 , Table 2 ) and cerebellum (Suppl. Fig.  S3, Fig. 4 , Table 3 ) there were no differences in SBDP145 when the three mouse lines were compared to each other with the exception of the cortex in Tga20 compared to WT on day 1. Lastly, we also observed varied and low levels of SBDP120 at days 1, 3 and 7 post-CHI in the cortex and cerebellum of all three mouse lines (indicated with arrowheads, Suppl. Figs. S2, S3 ). Since these SBDP120 levels were much lower and more variable than those of SBDP145, they were not quantified.
For glial cell markers in the three mouse lines, compared to sham controls, there were significant overall increases in intact GFAP and GFAP-44K in the cortex at all time points post CHI. However, there were no significant differences in the levels of intact GFAP and GFAP-44K when comparing the three mouse lines to each other. In addition, while the highest levels of intact GFAP in the cortex were observed on day 7 after CHI, cortical GBDP-44K began to rise on day 1, and plateaued on day 3 with similar levels on day 7 in all three mouse lines (Suppl. Fig. S2, Fig. 3 , Table 2 ).
Compared to sham, the glial cell marker, intact GFAP, was significantly increased in all three mouse lines only on day 7 in the post-CHI cerebellum (Suppl. Fig. S3, Fig. 4, Table 3 ). In addition, GBDP-44 K began to increase on day 1 which continued on days 3 and 7 in all three mouse lines. However, when we compared the post CHI cerebellar neural and glial biomarker levels across the three mouse lines, we failed to find any significant alterations in any of the three cerebellar biomarkers at any post CHI time points (Table 3) .
The calpain inhibitor SNJ-1945 was systemically administered (i.p. route) after CHI (or sham) as described above. We monitored changes in SBDP145, GFAP and GBDP-44K. We were especially interested in SBDP145 and GBDP-44K, as they are the direct BDPs of calpain cleavage [25] . When we examined the SNJ-1945 effects on each mouse line separately, we did observe a significant reduction of SBDP145 in the ipsilateral hippocampus of PrPKO and Tga20 mice on days 3 and 7 post CHI (Suppl. Fig. S1, Fig. 2, Table 1 ). There were no statistically significant differences in SBDP145 levels at any time point post CHI in the ipsilateral cortex in SNJ-1945 treated or untreated mice in any of the three mouse lines (Table 2) . However, when the ipsilateral cerebellum was examined, a statistically significant reduction in SBDP145 and GBDP-44K was observed at days 3 and 7 in all three SNJ-1945 treated mouse lines (Suppl. Fig. S3,  Fig. 4, Table 3 ). We suspect that the lack of more robust overall Fig. 4 . Graphical representation of densitometric quantification on the effects of PrP C expression and calpain inhibitor SNJ-1945 on neural and glial biomarkers in the ipsilateral cerebellum. Quantitative evaluation of target protein levels in Suppl. Fig. S3 was performed via computer-assisted densitometric scanning (Epson XL3500 scanner, Long Beach, CA, USA) and image analysis with Image J software (version 1.6) (NIH). Densitometric levels of SBDPs, GFAP and GBDP were standardized with same sample carbonic anhydrase-II level and expressed as arbitrary units. Data shown are mean ± SEM (n = 3-5) of target protein band intensity in lysate samples from individual mice.
SBDP145 and GBDP-44K reductions in the proteolytic biomarkers by SNJ-1945 could be due to the relatively small sample size at each time point (n = 3-5).
Interestingly, for the day 7 hippocampus groups, GBDP-44K seemed to be further elevated in CHI + SNJ mice when compared to CHI groups in all three mouse lines (WT, PrPKO, Tga20), although statistical significance was not achieved (might be due to relative low number of mice used) (Fig. 1) . Similarly, for day 7 cortex groups, the administration of SNJ-1945 treatment again tended to elevate GBDP-44K in all three mouse lines when compared to CHI alone. Most notable is the cortex of Tga20 mice where GBDP-44K in the CHI + SNJ group was significantly higher than in the CHI alone group (Fig. 2, Table 2 ). We speculate that this unexpected increase may result from overcompensation of calpain activity in astroglial cells after calpain inhibition subsided following the second and last dose of SNJ-1945 given at 24 h after CHI.
Post-CHI behavioral outcome and the effects of PrP c expression and SNJ-1945
Behavioral function was analyzed in mice at 7 days post CHI (and sham) using active place avoidance as described previously [39] and discussed in Section 2. In brief, the number of times a mouse entered a shock zone over a 10 min period was recorded. Significant learning and memory deficits after CHI were indicated if the sum of entrances into the shock zone after 4 sessions were statistically higher compared to sham mice. WT mice subjected to CHI displayed a statistically significant increase in the number of shock zone entrances compared to the sham animals. In contrast, CHI did not alter the learning and memory of PrPKO mice when compared to both sham-treated PrPKO mice and CHI-treated WT mice. CHI-treated Tga20 mice displayed a statistically significant increase in the number of entrances into the shock zone compared to the Tga20 sham controls, as well as CHI-treated WT and PrPKO mice. In addition, treatment of WT, PrPKO and Tga20 mice with SNJ-1945 following CHI (or sham) did not significantly alter the behavior of the mice when compared to SNJ-1945 untreated CHI (or sham) mice (Fig. 5) .
Discussion
A number of potential biomarkers expressed in the CNS show increases in circulating plasma levels that are directly correlated with the severity of the brain injury and inversely with predicted C expression and calpain inhibition on cognitive function following CHI. WT, PrPKO and Tga20 mice were subjected to CHI or sham treated. At 7 days post CHI (or sham) learning and memory were assessed using active place avoidance as described in Section 2. After pre-training, each mouse was subjected to four 10 min trials and the number of times each mouse entered the shock zone was recorded. The number of mice used for each group are indicated on the figure. The total number of entrances into the shock zone for the four trials was recorded and plotted as mean ± SEM. outcomes. The non-erythrocytic ␣II-spectrin is mainly expressed in axons and presynaptic terminals. ␣II-spectrin is broken down by calpain and caspase-3, which are activated following TBI during neuronal necrosis and apoptosis, respectively. The level of SBDPs in CSF samples from patients with severe TBI are associated with clinical correlates of the severity of the brain injury, such as Glasgow Coma Scale scores, and could be used to improve the prediction of patient outcomes [40] [41] [42] . SBDPs have, therefore, been investigated as potential biomarkers of brain injury in rodents and humans [43, 44] . GFAP is a monomeric intermediate filament protein that serves as a useful marker for various types of brain damage from neurodegenerative diseases to severe TBI [45] [46] [47] [48] . GFAP appears to be highly vulnerable to proteolytic digestion in vitro and in vivo. Consequently, the form of GFAP found in biofluids is likely to be its GFAP BDPs [49] . After TBI, GFAP-BDPs are likely to be the product of overactive calpain, leading to their release from injured or degenerating glia cells [33] . Therefore, it appears that GFAP-BDPs are not only released subacutely during gliosis, but also appear within hours after glial damage from TBI.
We have summarized the overall results of our biomarker studies (Table 4) . This provides only a generalized picture of the influence of PrP C expression on pathophysiology over a 7 day period following severe head trauma. Biomarker SBDP145 is an indicator of neuronal cell injury while GFAP and GFAP-44K measure glial cell activation and glial cell injury, respectively.
The levels of the calpain-associated BDPs, SBDP145 and GBDP-44K indicate that in the impacted hippocampus, calpain activity increases early after severe head trauma and reaches a steady state and/or decreases in activity over the following 7 days which is followed by an increase in caspase-3 activity. The levels of PrP C expression, as demonstrated by the three mouse strains used in this study, had no influence on those biomarker patterns.
Following injury, calpain activity increased rapidly in the cortex of WT, PrPKO and Tga20 mice, with the highest levels of activity in WT mice. This increase in activity was short-lived in the WT mice and the rate of increase was slower in PrPKO and Tga20 suggesting that the level and extent of calpain activity is not dependent on PrP C expression.
Increases in CHI-induced calpain activity are reflected by a rise in SBDP145 and GBDP-44K as a result of proteolytic cleavage of ␣II-spectrin and GFAP, respectively. Although there were variations in the rate and quantity of the BDPs generated, this was not influenced by PrP C expression levels. Ironically, Pham et al. [17] reported a significant, yet subtle, increase of PrP C in plasma following primary blast TBI and suggested the use of the PrP C as a novel biomarker for blast TBI. These authors further describe a positive correlation between plasma levels of PrP C and increasing blast intensity. Our results, however, do not support a correlation between TBI and PrP C . It is possible that the nature of the TBI accounts for the conflicting results with blast TBI causing a physiological effect that is not duplicated by CHI.
Surprisingly, treatment of mice with the calpain inhibitor, SNJ-1945, did not appear to have a major effect on the levels of BDPs in the hippocampus and cortex although an effect of SNJ-1945 was observed in the cerebellum. We hypothesized that this might be a function of the number of mice in each group that affected the statistical significance.
PrP C is a ubiquitous, highly conserved, membrane-bound glycoprotein found in many cell types but predominantly expressed in the CNS [50] . Functions associated with PrP C include cell signaling and neuroprotection [50] . Since the PrPKO mice have no overt phenotype, it is clear that PrP C is not essential for survival [51, 52] . However, genetic compensation and developmental plas-ticity may result in the functions of PrP C being replaced by another, as yet unidentified, protein. Our studies clearly demonstrate that calpain and caspase-3, and thus cell necrosis and apoptosis, are activated following severe head injury. This conclusion was based on the detection of BDPs from ␣II-spectrin and GFAP. However, it was surprising that the level of PrP C expression did not influence either necrosis or apoptosis. We expected that TBI would result in either increased PrP C and/or that high levels of PrP C would have a beneficial affect through inhibiting the proteolytic activities of calpain and/or caspase. This was not the finding and thus leaves the physiological role of PrP C in the response to TBI an enigma.
